<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03548129</url>
  </required_header>
  <id_info>
    <org_study_id>phosphomycin</org_study_id>
    <nct_id>NCT03548129</nct_id>
  </id_info>
  <brief_title>the Use of Fosfomycin as a Single Dose Oral Treatment of Asymptomatic Bacteriuria</brief_title>
  <official_title>Empirical Use of Fosfomycin as a Single Dose Oral Treatment of Asymptomatic Bacteriuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary tract infections (UTIs) are the most commonly occurring bacterial infections in&#xD;
      women, Asymptomatic bacteriuria (AB) is a common complication during pregnancy, with a&#xD;
      prevalence of 2-10%. It has been associated with a greater incidence of symptomatic urinary&#xD;
      tract infection (UTI), as well as foetal and obstetric complications. Appropriate treatment&#xD;
      reduces the incidence of UTI by 80-90%, as well as the risk of a premature birth and&#xD;
      low-birth-weight baby Fosfomycin trometamol (Monuril) is approved in numerous countries&#xD;
      worldwide, including various European countries and the USA, mainly for the treatment of&#xD;
      uncomplicated UTIs&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to compare between the efficacy of empirical use of fosfomycin trometamol and&#xD;
      the use of selected antimicrobials according to urinary culture and sensitivity in curing&#xD;
      asymptomatic bacteriuria.&#xD;
&#xD;
      All women included in the study will be counseled regarding mode of intervention and informed&#xD;
      consent will be obtained. All cases will be subjected to complete history taking, routine&#xD;
      antenatal examination and investigations including complete blood picture, kidney functions&#xD;
      and urine analysis, treatment of genital infection if diagnosed. Routine obstetric ultrasound&#xD;
      examination.&#xD;
&#xD;
      Patients will be randomized into two groups:&#xD;
&#xD;
        1. Group (A): Fosfomycin group (FG); where all patients will receive empirical 3 gm oral&#xD;
           fosfomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after&#xD;
           meals preferably in the evening before bed time after emptying the bladder.&#xD;
&#xD;
           The contents of 1 packet of Monuril will be dissolved in a glass of water or another&#xD;
           non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take&#xD;
           fosfomycin in its dry form.&#xD;
&#xD;
           Nature: also known as phosphomycin, phosphonomycin, is a broad-spectrum antibiotic,&#xD;
           produced by certain Streptomyces species, although it can now be made by chemical&#xD;
           synthesis.&#xD;
&#xD;
           Trade name: Monuril Company: Zambon, Pharma Con Company, Switzerland&#xD;
&#xD;
        2. Group (B): Culture specific group (CG): where all patients will receive oral antibiotic&#xD;
           according to urine culture and sensitivity, oral antibiotics will be given in the form&#xD;
           of five days regimen.&#xD;
&#xD;
      How the urine sample will be collected? The caregiver will give the patient a sterile cup and&#xD;
      lid, and advice her to wash herself completely then clean the perineal area from anterior to&#xD;
      posterior by water and in standing position as male begin to urinate then stop urinating put&#xD;
      the sterile cup and catch the rest of urine in it. Do not touch the inside of the cup or the&#xD;
      lid. Put the lid on the cup.&#xD;
&#xD;
      One week after completing the course of treatment all patients included in the study will be&#xD;
      subjected to colony count evaluation, to figure out the need for:&#xD;
&#xD;
        1. Urine culture in fosfomycin group in case of inadequate response to treatment and to&#xD;
           give antibiotic according.&#xD;
&#xD;
        2. The change of duration or the type of antibiotic in case of inadequate response to&#xD;
           initial treatment in the culture group.&#xD;
&#xD;
      Outcomes&#xD;
&#xD;
      Primary:&#xD;
&#xD;
        -  Resolution of asymptomatic bacteriuria as measured by colony count.&#xD;
&#xD;
        -  Time frame: 1 week&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        1. Side effects of fosfomycin as, nausea, diarrhea, headache, vaginal itching, runny nose,&#xD;
           back pain Side effects from other antibiotics in culture and sensitivity group&#xD;
&#xD;
        2. Need for further treatment, either extending the course of treatment into 5 or 7 days&#xD;
           regimen or changing the antibiotic in case of inadequate initial response.&#xD;
&#xD;
        3. Need for further investigations, as urine culture and sensitivity for fosfomycin group&#xD;
           in case of inadequate response on empirical treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of asymptomatic bacteriuria</measure>
    <time_frame>1 week</time_frame>
    <description>Decline in colony forming unit (CFU)/mL or absence of bacterial growth after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for further treatment</measure>
    <time_frame>1 week</time_frame>
    <description>Either extending the course of treatment into 5 or 7 days regimen or changing the antibiotic in case of inadequate initial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for further investigations</measure>
    <time_frame>1 week</time_frame>
    <description>Need for urine culture and sensitivity in fosfomycin group in case of inadequate response on empirical treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse drug reactions .</measure>
    <time_frame>1 week</time_frame>
    <description>Incidence of adverse drug reactions as nausea, diarrhea, headache, vaginal itching, runny nose, back pain Side effects from other antibiotics in culture and sensitivity group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Fosfomycin group (FG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder.&#xD;
The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form.&#xD;
Response to treatment will be assessed by post-treatment urine culture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Culture specific group (CG):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen.&#xD;
Response to treatment will be assessed by post-treatment urine culture.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phosphomycin</intervention_name>
    <description>Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach</description>
    <arm_group_label>Fosfomycin group (FG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Culture specific antibiotic therapy</intervention_name>
    <description>Culture-specific antibiotic treatment for 5 days</description>
    <arm_group_label>Culture specific group (CG):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pre-treatment Urine Culture</intervention_name>
    <description>Mid-stream urine sample will be cultured and number of CFU per mL will be determined.</description>
    <arm_group_label>Culture specific group (CG):</arm_group_label>
    <arm_group_label>Fosfomycin group (FG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Antimicrobial sensitivity testing</intervention_name>
    <description>Susceptibility of urinary pathogens to various antimicrobials</description>
    <arm_group_label>Culture specific group (CG):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Post-treatment urine culture</intervention_name>
    <description>Mid-stream urine sample will be cultured and number of CFU per mL will be determined.</description>
    <arm_group_label>Culture specific group (CG):</arm_group_label>
    <arm_group_label>Fosfomycin group (FG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pregnant patients from 13 weeks to 36 weeks gestation.&#xD;
&#xD;
          2. Pus cells in urine analysis &gt;5/HPF.&#xD;
&#xD;
          3. â‰¥ 105 colony-forming units (CFU) per millilitre of the same microorganisms in two&#xD;
             consecutive cultures.&#xD;
&#xD;
          4. No symptoms or sings suggestive of urinary tract infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of any urinary symptoms as burning micturition, hesitancy&#xD;
&#xD;
          2. Fever and loin pain.&#xD;
&#xD;
          3. Diabetes mellitus.&#xD;
&#xD;
          4. Known to be allergic from any of the antimicrobial ingredients.&#xD;
&#xD;
          5. Not using any antimicrobial during the course of treatment for any other infection.&#xD;
&#xD;
          6. Not known to have any congenital urinary anomalies.&#xD;
&#xD;
          7. If the patient is taking medications that interact with fosfomycin as:&#xD;
&#xD;
               -  Anorexiants (eg, phentermine) or certain sympathomimetics (eg, albuterol,&#xD;
                  amphetamine, pseudoephedrine) because the risk of their side effects may be&#xD;
                  increased by fosfomycin.&#xD;
&#xD;
               -  Lithium or tetracyclines because their effectiveness may be decreased by&#xD;
                  fosfomycin.&#xD;
&#xD;
               -  Metoclopramide because it may decrease fosfomycin's effectiveness.&#xD;
&#xD;
          8. Impaired kidney functions (creatinine's clearance is &lt;80 ml/min.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Samy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M Samy</affiliation>
  </overall_official>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>mohammed mahmoud samy</investigator_full_name>
    <investigator_title>Lecturer in Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacteriuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Fosfomycin</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

